AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3916836 — intervention group
Group type: COMPARATOR
Intervention: Decadron (3.3 mg of dexamethasone)
Number of subjects: 138
Study 31467447 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid genome sequencing (GS)
Number of subjects: 23
Study 27593706 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-reflux surgery (ARS)
Number of subjects: 245
Study 27593706 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (OME) 20-60 mg daily
Number of subjects: 245
Study 27593706 — intervention group
Group type: COMPARATOR
Intervention: Both ARS and OME
Number of subjects: 245
Study 25665607 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 87
Study 25665607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 22900530 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic handrim wheelchair exercise (30-40% HRR) on a treadmill, 16 weeks, 2 times per week, 30 min per session
Number of subjects: 40
Study 20647241 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 82
Study 20647241 — intervention group
Group type: COMPARATOR
Intervention: Usual care by the general practitioner (GP)
Number of subjects: 82
Study 19782791 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Number of subjects: 2331
Study 19782791 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol Visual Analog Scale (VAS)
Number of subjects: 2331
Study 17185206 — intervention group
Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes
Number of subjects: 35
Study 17185206 — intervention group
Group type: COMPARATOR
Intervention: High-yield nicotine cigarettes
Number of subjects: 35
Study 15342613 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg etoricoxib alone and following daily doses of 400 mg ketoconazole
Number of subjects: 24
Study 15342613 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg etoricoxib alone and following daily doses of 600 mg rifampin
Number of subjects: 24
Study 15342613 — intervention group
Group type: COMPARATOR
Intervention: 120 mg etoricoxib once daily for 11 days
Number of subjects: 24
Study 11727884 — intervention group
Group type: EXPERIMENTAL
Intervention: Millon Clinical Multiaxial Inventory (MCMI-II)
Number of subjects: 275
Study 11727884 — intervention group
Group type: COMPARATOR
Intervention: Structured Clinical Interview for DSM-III-R (SCID-II)
Number of subjects: 275
Study 9737283 — intervention group
Group type: EXPERIMENTAL
Intervention: K4 (n=103)
Number of subjects: 220
Study 9737283 — intervention group
Group type: COMPARATOR
Intervention: K5 (n=117)
Number of subjects: 220
Study 9737283 — intervention group
Group type: EXPERIMENTAL
Intervention: K4 (n=103) and K5 (n=117)
Number of subjects: 220
Study 8074755 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (three 400‐mg doses)
Number of subjects: 55
Study 8074755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2899357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal application of local anesthetic (bupivacaine or cocaine)
Number of subjects: 17
Study 2899357 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (saline)
Number of subjects: 17
Study 29797800 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention alongside CPAP treatment
Number of subjects: 0
Study 29797800 — intervention group
Group type: COMPARATOR
Intervention: CPAP treatment
Number of subjects: 0
Study 26861639 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 5, 10, 20, and 30 hPa during CPR with various ventilators (Evita® V500, Medumat® Transport, Oxylator® EMX, Oxylog® 2000, Oxylog® 3000, Primus®, Servo®-i, Wenoll® diver rescue system)
Number of subjects: 0
Study 26861639 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation CPR (as reported in literature)
Number of subjects: 0
Study 25180908 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe mental illness (SMI) women
Number of subjects: 303
Study 25180908 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe mental illness (SMI) men
Number of subjects: 303
Study 25180908 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe mental illness (SMI) victims
Number of subjects: 303
Study 25180908 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe mental illness (SMI) female victims
Number of subjects: 303
Study 25180908 — intervention group
Group type: COMPARATOR
Intervention: General population women (control)
Number of subjects: 303
Study 25180908 — intervention group
Group type: COMPARATOR
Intervention: General population men (control)
Number of subjects: 303
Study 25180908 — intervention group
Group type: COMPARATOR
Intervention: General population victims (control)
Number of subjects: 303
Study 25180908 — intervention group
Group type: COMPARATOR
Intervention: General population female victims (control)
Number of subjects: 303
Study 22588361 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/day)
Number of subjects: 16
Study 22588361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flour capsule)
Number of subjects: 16
Study 20634084 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of autologous platelet-rich plasma
Number of subjects: 140
Study 20634084 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical leg wound closure and care (Control)
Number of subjects: 140
Study 19070268 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microg/kg/min
Number of subjects: 60
Study 19070268 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.15 microg/kg/min
Number of subjects: 60
Study 19070268 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 microg/kg/min
Number of subjects: 60
Study 19070268 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 microg/kg/min remifentanil)
Number of subjects: 60
Study 19070268 — intervention group
Group type: EXPERIMENTAL
Intervention: All remifentanil groups
Number of subjects: 60
Study 16652216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiberix and Infanrix‐DTPa (primary vaccination)
Number of subjects: 61
Study 16652216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiberix (booster dose)
Number of subjects: 61
Study 16652216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiberix and Infanrix‐DTPa (booster dose)
Number of subjects: 61
Study 12589450 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolically cued movements
Number of subjects: 0
Study 12589450 — intervention group
Group type: COMPARATOR
Intervention: Directly cued movements
Number of subjects: 0
Study 12589450 — intervention group
Group type: COMPARATOR
Intervention: Mixed cuing (one directly cued, one symbolically cued)
Number of subjects: 0
Study 12589450 — intervention group
Group type: EXPERIMENTAL
Intervention: Compatible trials
Number of subjects: 0
Study 12589450 — intervention group
Group type: EXPERIMENTAL
Intervention: Incompatible trials
Number of subjects: 0
Study 10853207 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 130
Study 10853207 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg plus dexamethasone 8 mg intravenously
Number of subjects: 130
Study 9483021 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (dyadic support from former patients)
Number of subjects: 55
Study 9483021 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 55
Study 8339858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponalrestat (600 mg per day for 3 months)
Number of subjects: 30
Study 8339858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3522040 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 240 mg I/ml
Number of subjects: 49
Study 3522040 — intervention group
Group type: COMPARATOR
Intervention: metrizamide 240 mg I/ml
Number of subjects: 49
Study 29234966 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative multidisciplinary program for antibiotic prophylaxis
Number of subjects: 0
Study 26992038 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EX), n = 15, 24 weeks
Number of subjects: 22
Study 26992038 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (SED), n = 7, 24 weeks
Number of subjects: 22
Study 26992038 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EX)
Number of subjects: 22
Study 26992038 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (SED)
Number of subjects: 22
Study 24786013 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally soluble film (OSF) of 50 mg sildenafil
Number of subjects: 48
Study 24786013 — intervention group
Group type: COMPARATOR
Intervention: Film-coated tablet (FCT) of 50 mg sildenafil
Number of subjects: 48
Study 22858078 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided management
Number of subjects: 151
Study 22858078 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) management
Number of subjects: 151
Study 20376520 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPAS-Family
Number of subjects: 34
Study 20376520 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback
Number of subjects: 34
Study 18334811 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador M 5 mg spezial (IM spez)
Number of subjects: 33
Study 18334811 — intervention group
Group type: COMPARATOR
Intervention: Control group (without mistletoe)
Number of subjects: 33
Study 15806403 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytraumatized children
Number of subjects: 0
Study 15806403 — intervention group
Group type: COMPARATOR
Intervention: Polytraumatized adults
Number of subjects: 0
Study 15806403 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytraumatized children and adults
Number of subjects: 0
Study 12902441 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, etoposide, and carboplatin (experimental arm)
Number of subjects: 614
Study 12902441 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin, etoposide, and vincristine (standard arm)
Number of subjects: 614
Study 12902441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 614
Study 10078556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (20 IU H-Insulin 100 Hoechst)
Number of subjects: 18
Study 10078556 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (2.7 mg/ml m-Cresol)
Number of subjects: 18
Study 7851587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GnRH-a (250 micrograms SC leuprolide acetate) and hMG with elevated LH (> 35 mIU/mL)
Number of subjects: 203
Study 7851587 — intervention group
Group type: COMPARATOR
Intervention: Low-dose GnRH-a (250 micrograms SC leuprolide acetate) and hMG with non-elevated LH (< 35 mIU/mL)
Number of subjects: 203
Study 2184694 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 0.1 mg/kg
Number of subjects: 54
Study 2184694 — intervention group
Group type: EXPERIMENTAL
Intervention: piritramide 0.1 mg/kg
Number of subjects: 54
Study 2184694 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 7387140 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin 1.0 mg/kg
Number of subjects: 0
Study 7387140 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 1.0 mg/kg
Number of subjects: 0
Study 7387140 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin 2.5 mg/kg
Number of subjects: 0
Study 7387140 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 2.5 mg/kg
Number of subjects: 0
Study 7387140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study 30879607 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (n = 53)
Number of subjects: 160
Study 30879607 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game group (n = 56)
Number of subjects: 160
Study 30879607 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 51)
Number of subjects: 160
Study 28634972 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day treatment course with prednisone
Number of subjects: 311
Study 28634972 — intervention group
Group type: COMPARATOR
Intervention: 14-day treatment course with prednisone
Number of subjects: 311
Study 25889796 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Learning Plan (PLP) supported by an induction meeting
Number of subjects: 143
Study 25889796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PLP or induction meeting)
Number of subjects: 143
Study 23410849 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute brief intervention
Number of subjects: 278
Study 23410849 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-minute brief intervention
Number of subjects: 278
Study 23410849 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 278
Study 21803519 — intervention group
Group type: EXPERIMENTAL
Intervention: Basilic vein transposition (BBAVF)
Number of subjects: 57
Study 21803519 — intervention group
Group type: COMPARATOR
Intervention: AV graft (AVG)
Number of subjects: 57
Study 19118913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 10mg bid
Number of subjects: 291
Study 19118913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 25mg bid
Number of subjects: 291
Study 19118913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50mg bid
Number of subjects: 291
Study 19118913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 17551890 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD case management protocol
Number of subjects: 50
Study 17551890 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 50
Study 15626162 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at 2 Hz
Number of subjects: 34
Study 15626162 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at 100 Hz
Number of subjects: 34
Study 15626162 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at alternating frequency of 2 Hz and 100 Hz (2/100 Hz)
Number of subjects: 34
Study 15626162 — intervention group
Group type: COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation
Number of subjects: 34
Study 15626162 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at 2/100 Hz
Number of subjects: 34
Study 15516630 — intervention group
Group type: EXPERIMENTAL
Intervention: Traveling to an endemic area 8-14 days before disease onset
Number of subjects: 0
Study 15516630 — intervention group
Group type: EXPERIMENTAL
Intervention: Traveling 1-7, 15-21, or 22-30 days before disease onset
Number of subjects: 0
Study 15516630 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of protection against mosquitoes
Number of subjects: 0
Study 9852387 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 2 mg estradiol (E2) for 12 days, followed by 2 mg E2 and 1 mg norethisterone acetate for 10 days, then 1 mg E2 for 6 days, cyclically during 6 months.
Number of subjects: 50
Study 9852387 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the first 3 months, followed by the same HRT as the first group for the last 3 months.
Number of subjects: 50
Study 8770316 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (16 g i.v.)
Number of subjects: 9
Study 8770316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2287058 — intervention group
Group type: EXPERIMENTAL
Intervention: BMY-28100 (750 mg daily, divided into 3 administrations for at least 14 days)
Number of subjects: 172
Study 2287058 — intervention group
Group type: COMPARATOR
Intervention: CCL (cefaclor, 1,500 mg daily, divided into 3 administrations for at least 14 days)
Number of subjects: 172
Study 6169509 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (20% benzocaine)
Number of subjects: 53
Study 6169509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 31477676 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy self-management intervention (7 sessions over 5 weeks)
Number of subjects: 52
Study 31477676 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy self-management intervention
Number of subjects: 52
Study 31477676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 52
Study 31477676 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 27557833 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant 180 mg
Number of subjects: 0
Study 27557833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26811055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based game (3 × 10 min)
Number of subjects: 16
Study 26811055 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 16
Study 25086821 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined internal and external fixation (CIEF)
Number of subjects: 44
Study 25086821 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive percutaneous plate osteosynthesis (MIPPO)
Number of subjects: 44
Study 22277140 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol controlled‐release plus lisinopril (C+L)
Number of subjects: 25
Study 22277140 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide plus lisinopril (H+L)
Number of subjects: 25
Study 19169910 — intervention group
Group type: COMPARATOR
Intervention: Suction Cup (SC) method
Number of subjects: 36
Study 19169910 — intervention group
Group type: COMPARATOR
Intervention: Soft Tissue Stiffness Meter (STSM) method
Number of subjects: 36
Study 17559737 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (200 mg once daily)
Number of subjects: 36
Study 17559737 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (200 mg once daily)
Number of subjects: 36
Study 17559737 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of posaconazole and phenytoin (both 200 mg once daily)
Number of subjects: 36
Study 16299322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insufflation of MCP-CRM197 conjugate vaccine mixed with chitosan (2 doses, 28 days apart)
Number of subjects: 36
Study 16299322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insufflation of MCP-CRM197 conjugate vaccine mixed with chitosan (1 dose)
Number of subjects: 36
Study 16299322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insufflation of MCP-CRM197 conjugate vaccine mixed with chitosan
Number of subjects: 36
Study 16299322 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of MCP-CRM197 conjugate vaccine in alum
Number of subjects: 36
Study 11927206 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk ('selected') patients
Number of subjects: 0
Study 11927206 — intervention group
Group type: COMPARATOR
Intervention: Risk-adjustment methodology
Number of subjects: 0
Study 9628497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone cement (Oto-Cem) reconstruction of the ossicular chain
Number of subjects: 9
Study 9628497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone cement (Oto-Cem) reconstruction with stapes prosthesis
Number of subjects: 9
Study 9628497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone cement (Oto-Cem) reconstruction (incus to oval window repairs)
Number of subjects: 9
Study 7697308 — intervention group
Group type: EXPERIMENTAL
Intervention: Active administration of specific bacterial cultures in fermented milk
Number of subjects: 40
Study 30975673 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine CXCL10 monitoring with study biopsy for subclinical rejection and treatment per protocol.
Number of subjects: 250
Study 30975673 — intervention group
Group type: COMPARATOR
Intervention: Routine post‐transplant monitoring (Control).
Number of subjects: 250
Study 30975673 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine CXCL10 monitoring strategy.
Number of subjects: 250
Study 30624128 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 610
Study 30624128 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 610
Study 30624128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over from Leuprolide to Degarelix
Number of subjects: 610
Study 26968970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 1247
Study 26968970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study 24127687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 0
Study 24127687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22820612 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 16
Study 22820612 — intervention group
Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor-based regimen
Number of subjects: 16
Study 22820612 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 individuals)
Number of subjects: 16
Study 19561150 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dilution haemodiafiltration (HDF)
Number of subjects: 19
Study 19561150 — intervention group
Group type: COMPARATOR
Intervention: Low-flux haemodialysis (HD)
Number of subjects: 19
Study 17227324 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 815
Study 17227324 — intervention group
Group type: COMPARATOR
Intervention: Oral medication treatment
Number of subjects: 815
Study 17227324 — intervention group
Group type: COMPARATOR
Intervention: Diet only treatment
Number of subjects: 815
Study 14997947 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of sport psychology and its personal benefits
Number of subjects: 124
Study 14997947 — intervention group
Group type: COMPARATOR
Intervention: Discussion of sports experiences
Number of subjects: 124
Study 11722955 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg leucine x kg(‐1) x d(‐1)
Number of subjects: 20
Study 11722955 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 mg leucine x kg(‐1) x d(‐1)
Number of subjects: 20
Study 11722955 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg leucine x kg(‐1) x d(‐1)
Number of subjects: 20
Study 11722955 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg leucine x kg(‐1) x d(‐1)
Number of subjects: 20